- Home
- TSVT
TSVT
2seventy bio Inc.
as 07-26-2024 4:00pm EST
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 231.8M | IPO Year: | N/A |
| Target Price: | $10.67 | AVG Volume (30 days): | 549.5K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.53 - $8.08 | Next Earning Date: | 08-12-2024 |
| Revenue: | $71,201,000 | Revenue Growth: | -42.90% |
| Revenue Growth (this year): | -39.07% | Revenue Growth (next year): | 29.32% |
Stock Insider Trading Activity of 2seventy bio Inc. (TSVT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Eatwell Victoria | TSVT | Chief Financial Officer | Jul 1 '24 | Sell | $4.02 | 12 | $48.21 | 341,332 | SEC Form 4 |
| Eatwell Victoria | TSVT | Chief Financial Officer | Jun 3 '24 | Sell | $4.18 | 1,167 | $4,880.74 | 95,480 | SEC Form 4 |
| Snow Jessica | TSVT | See Remarks | Jun 3 '24 | Sell | $4.18 | 649 | $2,714.31 | 55,622 | SEC Form 4 |
| Snow Jessica | TSVT | See Remarks | May 3 '24 | Sell | $4.91 | 15 | $73.65 | 56,271 | SEC Form 4 |
| Casdin Capital, LLC | TSVT | Director | Mar 26 '24 | Buy | $5.10 | 40,000 | $203,992.00 | 2,000,000 | SEC Form 4 |
| Casdin Capital, LLC | TSVT | Director | Mar 21 '24 | Buy | $4.90 | 300,000 | $1,470,990.00 | 1,482,623 | SEC Form 4 |
| Casdin Capital, LLC | TSVT | Director | Mar 21 '24 | Buy | $5.12 | 147,377 | $754,069.16 | 1,630,000 | SEC Form 4 |
| Casdin Capital, LLC | TSVT | Director | Mar 21 '24 | Buy | $5.07 | 330,000 | $1,673,991.00 | 1,960,000 | SEC Form 4 |
| Baird William D III | TSVT | Chief Operating Officer | Jan 5 '24 | Sell | $3.75 | 1,380 | $5,179.97 | 161,335 | SEC Form 4 |
| Gregory Philip D | TSVT | Chief Scientific Officer | Jan 5 '24 | Sell | $3.75 | 795 | $2,984.11 | 230,842 | SEC Form 4 |
| Leschly Nick | TSVT | President and CEO | Jan 5 '24 | Sell | $3.75 | 1,554 | $5,833.09 | 1,085,476 | SEC Form 4 |
| Baird William D III | TSVT | Chief Operating Officer | Jan 3 '24 | Sell | $3.87 | 33,651 | $130,178.89 | 162,715 | SEC Form 4 |
| Gregory Philip D | TSVT | Chief Scientific Officer | Jan 3 '24 | Sell | $3.87 | 25,613 | $99,083.89 | 231,637 | SEC Form 4 |
| Leschly Nick | TSVT | President and CEO | Jan 3 '24 | Sell | $3.87 | 72,312 | $279,738.97 | 1,087,030 | SEC Form 4 |
Latest 2seventy bio Inc. News
TSVT Breaking Stock News: Dive into TSVT Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Broker Revenue Forecasts For 2seventy bio, Inc. (NASDAQ:TSVT) Are Surging Higher
Business Wire
a month ago
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
Simply Wall St.
2 months ago
Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
Simply Wall St.
2 months ago
Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Simply Wall St.
2 months ago
Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
Compare TSVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TSVT 2seventy bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.